|Day Low/High||94.51 / 97.38|
|52 Wk Low/High||53.06 / 123.99|
Jim Cramer weighs in on Netflix, iRobot, Exact Sciences, Rite Aid, Inmode and more.
Jim Cramer says that while recession fears hit stocks Tuesday, he thinks there are other rational reasons for the pullback.
Let's check the charts and indicators to see if this a good time and location to go long EXAS.
Jim Cramer takes a look at PayPal, NextEra Energy, Sarepta Therapeutics, CEL-SCI, MFA Financial, Fidelity National Services and more.
Analyst Bruce Jackson likes the prospects for the producer of a DNA-based colon-cancer-screening test for use at home.
Stool DNA test offers a sensitive, noninvasive, at-home option to screen for colorectal cancer, second deadliest cancer in U.S.
Open jobs offer opportunity to join dynamic company
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in EXACT Sciences Corp. , where a total of 6,258 contracts have traded so far, representing approximately 625,800 underlying shares.
ABOUT HALF OF THOSE TESTED WITH COLOGUARD WERE PREVIOUSLY UNSCREENED
NEW ORLEANS, Aug. 2, 2019 /PRNewswire/ -- Former Attorney General of Louisiana Charles C.
Citron analyst sees 'indestructible moat' around genetic-testing company's business.
Jim Cramer talks about what investors need to do ahead of an expected rate cut and amid earnings and trade upheaval.
NEW YORK, July 29, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Genomic Health, Inc.
Cancer diagnostics company Exact Sciences will acquire healthcare company Genomic Health for about $2.8 billion.
U.S. stock futures are mixed as Wall Street prepares for a likely quarter-point rate cut from the Federal Reserve; Beyond Meat reports earnings on Monday; Pfizer will combine its off-patent drugs business with Mylan; Exact Sciences reportedly is in negotiations to buy Genomic Health.
- Estimated Cologuard® market share increased to 5.7 percent during the second quarter
Joins two of the strongest brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth
Cancer diagnostics company Exact Sciences is in advanced talks to acquire Genomic Health for about $2.8 billion to strengthen its cancer-testing offerings, according to Bloomberg.
Hundreds of open positions offer opportunity to join growing company
MADISON, Wis., July 9, 2019 /PRNewswire/ -- Exact Sciences Corp.
Company's total lab processing capacity expected to reach 7 million by end of year
A roundup of Jim Cramer's thoughts on stocks of interest to Mad Money viewers.
By going after friendly trading partners and big tech Trump is forcing Wall Street to re-calibrate and lower valuations, Jim Cramer says.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.